Skip to main content
. 2021 Aug 17;11(10):2436–2445. doi: 10.1158/2159-8290.CD-21-0702

Figure 1.

Figure 1.

TROP2 expression and gene copy number and response to SG. A, Clinical characteristics, treatment history, and SG response data for the three autopsy series patients. PR, partial response; SD, stable disease; PD, progressive disease. B, TACSTD2/TROP2 copy number (top) and RNA expression (bottom) for all analyzed tumor specimens from each case. Note, white indicates diploid copy number. Key for lesion location: S, subcutaneous; P, pericardium; L, liver; U, lung; M, mediastinum; G, gallbladder; N, lymph node; B, brain; 1o, primary breast tumor. C, Hematoxylin and eosin (H&E) and TROP2 IHC show tumor TROP2 protein expression is absent in MGH-20 but shows intense membrane staining in MGH-18. Scale bars, 50 μm. D, Focal amplification of TACSTD2/TROP2 in pretreatment primary tumor and multiple metastatic lesions from MGH-18. Copy-number scale per B is shown for the indicated region of chromosome 1p of each lesion, indicating up to N = 5 TACSTD2/TROP2 copies. See also Supplementary Fig. S1 and Supplementary Table S1.